BioMed Research International

Novel Targets and Small Molecular Interventions for Liver Cancer


Publishing date
15 Aug 2014
Status
Published
Submission deadline
28 Mar 2014

Lead Editor

1Department and Institute of Hepatobiliary Surgery, Affiliated Drum Tower Hospital, Medical School, Nanjing University, Nanjing, China

2Intra-abdominal Transplant and Hepatobiliary Surgery, Westchester Medical Center of New York Medical College, NY, USA

3Department of Liver Surgery and Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China

4Department of Pathology and Hepatology, Beijing Institute of Infectious Diseases, Beijing 302 Hospital, Beijing, China


Novel Targets and Small Molecular Interventions for Liver Cancer

Description

Liver cancer represents the sixth most common cancer worldwide. The extremely poor prognosis makes it rank the third in cancer-related deaths. Despite the current improvements, therapeutic methods for liver cancer are still limited and the outcome remains unsatisfactory. This dilemma is at least partly because of the lack of well-characterized molecular targets and effective interventions. Advancements in mechanism of liver cancer have shed light on the pathogenesis of this disastrous disease and provided promising targets for the development of next-generation therapies. With proper structures, some small molecules may combine ideal bioavailability and selective therapeutic effects. Compound screening based on molecular targets leads to the innovation of numerous novel interventions for liver cancer. Among them, the multikinase inhibitor sorafenib has become first-line therapy for advanced-stage hepatocellular carcinoma and significantly improved the outcome. Exploiture of ethnic medicine also revealed a large resource of small molecules for the treatment of liver cancer from well-established regimens. The combination of key molecules and small compound interventions has been proven effective. Upcoming research on novel molecular targets and discovery of targeted small molecules for liver cancer will have distinguished significance in novel drug development and may have direct impact on clinical management.

We invite authors to contribute original research and review articles that will stimulate the lasting exertion to unveil novel molecular targets and small molecular interventions for liver cancer. Potential topics include, but are not limited to:

  • Novel molecular targets in carcinogenesis, progression, and metastasis of liver cancer
  • Clinical significance of molecular pathways in liver cancer
  • Screening and evaluation of potential diagnostic or therapeutic small molecules
  • Structural design and chemical modification of small molecules
  • Small radioactive molecules for liver cancer
  • Pharmacodynamics, pharmacokinetics, and toxicology of small molecules
  • Clinical evaluation of small molecular targeted interventions for liver cancer
  • Novel integrative and multimodal therapy with small molecules
  • Ethnopharmacology in liver cancer therapy

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/gastroenterology/ntsi/ according to the following time table:


Articles

  • Special Issue
  • - Volume 2014
  • - Article ID 148783
  • - Editorial

Novel Targets and Small Molecular Interventions for Liver Cancer

Chunping Jiang | Youmin Wu | ... | Jingmin Zhao
  • Special Issue
  • - Volume 2014
  • - Article ID 682197
  • - Research Article

Dehydroabietic Acid Derivative QC2 Induces Oncosis in Hepatocellular Carcinoma Cells

Guang Zhang | Chunping Jiang | ... | Yitao Ding
  • Special Issue
  • - Volume 2014
  • - Article ID 203693
  • - Review Article

[Retracted] Hepatocellular Carcinoma: Novel Molecular Targets in Carcinogenesis for Future Therapies

Gaetano Bertino | Shirin Demma | ... | Mariano Malaguarnera
  • Special Issue
  • - Volume 2014
  • - Article ID 764981
  • - Research Article

Hepatic Stellate Cell Coculture Enables Sorafenib Resistance in Huh7 Cells through HGF/c-Met/Akt and Jak2/Stat3 Pathways

Weibo Chen | Junhua Wu | ... | Yitao Ding
  • Special Issue
  • - Volume 2014
  • - Article ID 832712
  • - Research Article

A Critical Role for ZDHHC2 in Metastasis and Recurrence in Human Hepatocellular Carcinoma

Chuanhui Peng | Zhijun Zhang | ... | Shusen Zheng
  • Special Issue
  • - Volume 2014
  • - Article ID 732516
  • - Research Article

Baicalein Induces Apoptosis and Autophagy via Endoplasmic Reticulum Stress in Hepatocellular Carcinoma Cells

Zhongxia Wang | Chunping Jiang | ... | Baorui Liu
  • Special Issue
  • - Volume 2014
  • - Article ID 516518
  • - Research Article

BAG3 and HIF-1α Coexpression Detected by Immunohistochemistry Correlated with Prognosis in Hepatocellular Carcinoma after Liver Transplantation

Heng Xiao | Rongliang Tong | ... | Shusen Zheng
  • Special Issue
  • - Volume 2014
  • - Article ID 468605
  • - Research Article

Association between Two Common Polymorphisms and Risk of Hepatocellular Carcinoma: Evidence from an Updated Meta-Analysis

Zhaoming Wang | Lei Zhang | ... | Jianmin Bian
  • Special Issue
  • - Volume 2014
  • - Article ID 482926
  • - Research Article

MicroRNA-24 Modulates Aflatoxin B1-Related Hepatocellular Carcinoma Prognosis and Tumorigenesis

Yi-Xiao Liu | Xi-Dai Long | ... | Qiang Xia
  • Special Issue
  • - Volume 2014
  • - Article ID 742417
  • - Research Article

Reexpression of Let-7g MicroRNA Inhibits the Proliferation and Migration via K-Ras/HMGA2/Snail Axis in Hepatocellular Carcinoma

Ke-ji Chen | Ying Hou | ... | Feng Shen
BioMed Research International
 Journal metrics
See full report
Acceptance rate8%
Submission to final decision128 days
Acceptance to publication21 days
CiteScore5.300
Journal Citation Indicator-
Impact Factor-
 Submit Evaluate your manuscript with the free Manuscript Language Checker

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.